PUBLIC POLICIES FOR PROVISION OF DRUGS FOR DIABETES MELLITUS TYPE

ELORZA, MARÍA EUGENIA; MOSCOSO NEBEL; LAGO, FERNANDO P.

AAPS PHARMSCITECH

SPRINGER

Lugar: Arlington, Virginia (publicado en formato proceeding) ; Año: 2011 vol. 12 p. 16 - 16

1530-9932

The epidemiological transition has determined that some chronic diseases are nowadays the main causes of morbidity and mortality. Diabetes Mellitus Type 2 (DMII) affects 80% of diabetic population. Pharmacological treatment in general involves oral hypoglucemiants, and glibenclamide and metformin are the most commonly used (1). In Argentina, public policies from different levels of government guaranteed public provision of these drugs to the people without any type of health coverage: national law 23.753 (1989), provincial law 11.620 (1994) and REMEDIAR, a national program for access to generic drugs (2002). In 1996 PRODIABA, a provincial program which provides free oral hypoglucemiants for diabetic patients, was created. While both programs, REMEDIAR and PRODIABA should deliver glibenclamide 5 mg and metformin 500 mg, delays in the delivery of metformin determined the intervention of the municipality of Bahia Blanca (MBB). Local authorities had to provide this drug to ensure the treatment of type 2 diabetic population without health coverage. The objective of this paper is to quantify monetarily (expenditure) the current municipal provision of metfomin and the amount of this drug that should be allocated to potential type 2 diabetic patients if they had pharmacological treatment.